(Q50471485)

14 March 2018

title

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. (English)

1 reference

14 March 2018

0 references

19

1 reference

14 March 2018

Altynay Shigayeva

3

Altynay Shigayeva

1 reference

14 March 2018

Andrew E Simor

17

Andrew E Simor

1 reference

14 March 2018

Donald E Low

4

Donald E Low

1 reference

14 March 2018

David C. Richardson

13

David Richardson

1 reference

14 March 2018

Sigmund Krajden

11

Sigmund Krajden

1 reference

14 March 2018

Kevin Katz

9

Kevin Katz

1 reference

14 March 2018

Rachel Karen Green

5

Karen Green

1 reference

14 March 2018

Wallis Rudnick

1

Wallis Rudnick

1 reference

14 March 2018

Toronto Invasive Bacterial Diseases Network

20

Toronto Invasive Bacterial Diseases Network

1 reference

14 March 2018

Agron Plevneshi

6

Agron Plevneshi

1 reference

14 March 2018

Ian Kitai

10

Ian Kitai

1 reference

14 March 2018

Alicia Sarabia

15

Alicia Sarabia

1 reference

14 March 2018

author name string

Zhong Liu

2

1 reference

14 March 2018

Roslyn Devlin

7

1 reference

14 March 2018

James Downey

8

1 reference

14 March 2018

Krystyna Ostrowska

12

1 reference

14 March 2018

Susan Richardson

14

1 reference

14 March 2018

Michael Silverman

16

1 reference

14 March 2018

Gregory Tyrrell

18

1 reference

14 March 2018

language of work or name

English

0 references

publication date

5 October 2013

1 reference

14 March 2018

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 March 2018

volume

31

1 reference

14 March 2018

issue

49

1 reference

14 March 2018

page(s)

5863-5871

1 reference

14 March 2018

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Understanding the burden of pneumococcal disease in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Serotype replacement in disease after pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Impact of public vaccination programs on adult vaccination rates: Two examples from Ontario, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Volume matters: physician practice characteristics and immunization coverage among young children insured through a universal health plan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgary‐Area Streptococcus pneumoniae Research (CASPER) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Efficacy of pneumococcal vaccination in adults: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

The epidemiology of invasive pneumococcal disease in British Columbia following implementation of an infant immunization program: increases in herd immunity and replacement disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Clonal and Capsular Types Decide Whether Pneumococci Will Act as a Primary or Opportunistic Pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Epidemiological differences among pneumococcal serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

A role for Streptococcus pneumoniae in virus-associated pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.09.049

1 reference

14 March 2018

1 reference

14 March 2018